WO2009034134A3 - Use of natriuretic peptides for treating angioedema syndromes - Google Patents

Use of natriuretic peptides for treating angioedema syndromes Download PDF

Info

Publication number
WO2009034134A3
WO2009034134A3 PCT/EP2008/062067 EP2008062067W WO2009034134A3 WO 2009034134 A3 WO2009034134 A3 WO 2009034134A3 EP 2008062067 W EP2008062067 W EP 2008062067W WO 2009034134 A3 WO2009034134 A3 WO 2009034134A3
Authority
WO
WIPO (PCT)
Prior art keywords
syndromes
natriuretic peptides
urodilatin
hours
treating angioedema
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/062067
Other languages
French (fr)
Other versions
WO2009034134A2 (en
Inventor
Wolf-Georg Forssmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharis Biotec GmbH
Original Assignee
Pharis Biotec GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP08100213A external-priority patent/EP2078530A1/en
Application filed by Pharis Biotec GmbH filed Critical Pharis Biotec GmbH
Priority to US12/733,609 priority Critical patent/US8293711B2/en
Priority to ES08804032.4T priority patent/ES2575397T3/en
Priority to EP08804032.4A priority patent/EP2185183B1/en
Publication of WO2009034134A2 publication Critical patent/WO2009034134A2/en
Publication of WO2009034134A3 publication Critical patent/WO2009034134A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to the use of a natriuretic peptide, urodilatin, for treating patients suffering from acute drug induced angioedema, such as ACE inhibitor related adverse events. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously for 18 hours to 72 hours.
PCT/EP2008/062067 2007-09-11 2008-09-11 Use of natriuretic peptides for treating angioedema syndromes Ceased WO2009034134A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/733,609 US8293711B2 (en) 2007-09-11 2008-09-11 Use of natriuretic peptides for treating angioedema syndromes
ES08804032.4T ES2575397T3 (en) 2007-09-11 2008-09-11 Use of natriuretic peptides for the treatment of angioedema syndromes
EP08804032.4A EP2185183B1 (en) 2007-09-11 2008-09-11 Use of natriuretic peptides for treating angioedema syndromes

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07116164 2007-09-11
EP07116164.0 2007-09-11
EP08100213A EP2078530A1 (en) 2008-01-08 2008-01-08 Use of natriuretic peptides for treating angioedema syndromes
EP08100213.1 2008-01-08

Publications (2)

Publication Number Publication Date
WO2009034134A2 WO2009034134A2 (en) 2009-03-19
WO2009034134A3 true WO2009034134A3 (en) 2009-05-22

Family

ID=40091570

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/062067 Ceased WO2009034134A2 (en) 2007-09-11 2008-09-11 Use of natriuretic peptides for treating angioedema syndromes

Country Status (4)

Country Link
US (1) US8293711B2 (en)
EP (1) EP2185183B1 (en)
ES (1) ES2575397T3 (en)
WO (1) WO2009034134A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005027461D1 (en) 2004-04-21 2011-05-26 Enobia Pharma Inc CONJUGATES FOR INTRODUCTION TO BONE AND METHOD FOR THEIR USE IN THE INTRODUCTION OF PROTEINS FOR BONE
DK2510942T3 (en) 2005-04-07 2015-12-14 Cardiorentis Ag Use of natriuretic peptides for the treatment of heart failure
WO2011113825A1 (en) * 2010-03-15 2011-09-22 Wolf-Georg Forssmann Use of urodilatin for preparing a medicament for the treatment of cardiovascular, renal, pulmonary and neuronal syndromes while avoiding a rebound
JP6055779B2 (en) 2010-12-27 2016-12-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド Composition comprising natriuretic peptide and method of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US20140213520A1 (en) * 2013-01-25 2014-07-31 Cardiorentis Ltd. Methods of treating cardiovascular indications
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
JP6787894B2 (en) 2014-12-05 2020-11-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド Treatment of seizures with recombinant alkaline phosphatase
JP6868561B2 (en) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド How to treat subjects with alkaline phosphatase deficiency
JP6993961B2 (en) 2015-08-17 2022-01-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド Production of alkaline phosphatase
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFICIENT POSOLOGICAL REGIMES FOR NON-SPECIFIC TISSUE ALKALINE ENZYME PHOSPHATASE REPLACEMENT HYPOPHOSPHATASE (TNSALP) THERAPY
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
KR20240160671A (en) 2016-04-01 2024-11-11 알렉시온 파마슈티칼스, 인코포레이티드 Treating muscle weakness with alkaline phosphatases
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
EP3464573B1 (en) 2016-06-06 2026-03-04 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
EP3500289B1 (en) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa for use in treating tracheobronchomalacia
KR20190129058A (en) 2017-03-31 2019-11-19 알렉시온 파마슈티칼스, 인코포레이티드 How to treat hypophosphatase (HPP) in adults and adolescents
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
ES2972119T3 (en) 2018-08-10 2024-06-11 Alexion Pharma Inc Bone healing in implants using alkaline phosphatase
KR20220111693A (en) 2019-12-09 2022-08-09 알렉시온 파마슈티칼스, 인코포레이티드 Alkaline phosphatase polypeptides and methods of using the same
US12083169B2 (en) 2021-02-12 2024-09-10 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
WO2023099725A1 (en) * 2021-12-02 2023-06-08 Pharis Biotec Gmbh Pharmaceutical preparation containing a mixture of a natriuretic peptide (anp) and a peptidic inhibitor of the cxcr4 receptor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0369474A2 (en) * 1988-11-18 1990-05-23 Asahi Kasei Kogyo Kabushiki Kaisha Pharmaceutical composition for the treatment of cerebral edema
WO2004022579A2 (en) * 2002-09-06 2004-03-18 University Of South Florida Cellular delivery of natriuretic peptides
WO2006110743A1 (en) * 2005-04-07 2006-10-19 Cardiopep Pharma Gmbh Use of natriuretic peptide for treating heart failure

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3878231T2 (en) 1987-03-02 1993-05-27 Bissendorf Peptide Gmbh NEW CADIODILATIN FRAGMENT, PROCESS FOR THEIR PRODUCTION AND USE.
DE4216133A1 (en) * 1992-05-15 1993-11-18 Bissendorf Peptide Gmbh Use of urodilatin in lung and bronchial diseases
DE19951471A1 (en) * 1999-10-26 2001-05-03 Forssmann Wolf Georg Use of urodilatin for the treatment of chronic renal failure with residual kidney functions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0369474A2 (en) * 1988-11-18 1990-05-23 Asahi Kasei Kogyo Kabushiki Kaisha Pharmaceutical composition for the treatment of cerebral edema
WO2004022579A2 (en) * 2002-09-06 2004-03-18 University Of South Florida Cellular delivery of natriuretic peptides
WO2006110743A1 (en) * 2005-04-07 2006-10-19 Cardiopep Pharma Gmbh Use of natriuretic peptide for treating heart failure

Also Published As

Publication number Publication date
US20100204446A1 (en) 2010-08-12
US8293711B2 (en) 2012-10-23
WO2009034134A2 (en) 2009-03-19
ES2575397T3 (en) 2016-06-28
EP2185183A2 (en) 2010-05-19
EP2185183B1 (en) 2016-03-16

Similar Documents

Publication Publication Date Title
WO2009034134A3 (en) Use of natriuretic peptides for treating angioedema syndromes
WO2007081975A3 (en) Method of treating multiple sclerosis
WO2008050329A3 (en) Novel sirnas and methods of use thereof
EP2360258A3 (en) Aprotinin polypeptides for transporting a compound across the blood-brain barrier
WO2011080102A3 (en) Glp-1 analogues and derivatives
MY174002A (en) Combination theraphy for the treatment of diabetes
WO2011149964A3 (en) Methods for treating or preventing vascular graft failure
ZA200806778B (en) N-Hydroxyacrylamide compounds
TNSN07413A1 (en) Use of tfpi to treat severe bacterial infections
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
WO2008103378A3 (en) Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
WO2008066626A3 (en) METHODS FOR THE TREATMENT OF Aβ RELATED DISORDERS AND COMPOSITIONS THEREFOR
WO2007145589A8 (en) Peptides that are capable of binding to amyloid-beta peptide.
WO2007114902A3 (en) Alkylthiobenzylpiperidine compounds
WO2007114916A3 (en) Arylbenzylpiperidine compounds
WO2006121995A3 (en) Methods for treating nephrolithiasis
WO2007046842A3 (en) Composition for inhibition of cathepsin k
WO2008049881A3 (en) Polypeptides and pharmaceutical compositions comprising the same for the prevention and treatment of complications associated with infectious diseases
WO2008057599A3 (en) Methods for the treatment of abeta related disorders and compositions therefor
WO2007000770A3 (en) Protein kinase c inhibitors for prevention of insulin resistance and type 2 diabetes
WO2007047205A3 (en) Enzyme inhibitors of pai-1
JP2006523181A5 (en)
WO2006101909A3 (en) Combination therapy for treating or preventing diseases
WO2006029487A3 (en) Platelet factor 4 variant 1 (pf4var1) related inhibitors of angiogenesis
WO2009041026A1 (en) Cxcl10 production inhibitor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08804032

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008804032

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12733609

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE